Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiov
SMi Reports: SMi has released an exclusive interview with industry expert Dr Sigbjorn Gregusson, Managing Director, BioBank AS ahead of the upcoming Biobanking conference this September.
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte